The only FDA-approved treatment for patients with Lysosomal Acid Lipase Deficiency (LAL-D)1
KANUMA® (sebelipase alfa) is a hydrolytic lysosomal cholesteryl ester and triacylglycerol–specific enzyme indicated for the treatment of patients with a diagnosis of LAL-D.1
KANUMA is administered as an intravenous infusion under the supervision of a healthcare professional.1 For more information, download the full Prescribing Information and Dosing and Administration brochure below:
Getting Started on Kanuma® (sebelipase alfa)
KANUMA is approved by the U.S. Food and Drug Administration as a treatment for patients with a diagnosis of LAL-D.1
Here’s how OneSource™ can help you get your patients with LAL-D started on KANUMA:
Call the OneSource team at 1-888-765-4747. OneSource Customer Operations will work to facilitate order processing and delivery.
Ask your patient to sign the OneSource enrollment form to start working with a nurse case manager.
Download patient consent form
We’re Here to Help
Once you have decided that KANUMA® is right for your patient, OneSource is here to help. After your patient signs up, they will be matched with a dedicated Alexion nurse case manager who can help answer any questions about KANUMA or LAL-D.
OneSource is staffed by nurse case managers who provide one-to-one education, assistance with funding options and access to KANUMA, as well as ongoing treatment support for your patients living with LAL-D, and their caregivers.
Connect with Alexion: Medical Information